The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
|Articles|December 28, 2012
More-Complex Care, Not Fraud, Behind Higher ER Billing, Doc Argues
Advertisement
Fraud isn't at the root of a spike in providers' billing for emergency services, a new opinion piece in the New England Journal of Medicine asserts.
Rather, the piece's author writes, higher ER billing reflects both increasingly complex care provided in emergency departments over the past decade and more-accurate coding of that care.
Advertisement
Related to this article
In this Q&A, Rob Stransky of NiceRx explains how to screen patients for gray-market retatrutide use and why cost drives demand for unregulated peptides.
First-line IVF produced more live births than IUI within 7 months in couples with unexplained infertility.
Elafibranor and seladelpar normalized ALP in most patients with primary biliary cholangitis whose ALP was below the usual escalation threshold.
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
Most patients with MASH stay on resmetirom at 1 year, but Medicaid coverage was tied to lower odds of filling a first prescription within 30 days.
A 20-year review traces how immune checkpoint inhibitors became a cornerstone of lung cancer treatment.
David T. Plante, MD, PhD, explains that separating mood-related sleepiness from primary hypersomnia relies on the course of illness and sleep testing.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Asundexian, First FXIa Inhibitor to Prevent Repeat Stroke
2
How Plans, Clinicians Should Handle Gray-Market Retatrutide
3
IVF Beats IUI for Early Live Births in Unexplained Infertility
4
Phase 3 Data Back ALP Normalization as Treatment Goal in PBC
5